Copyright © 2000 by the European Society of Cardiology.
Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure
a London Health Sciences Centre, London, Canada
b HGH-McMaster Clinic, Hamilton, Canada
c Career Scientist of the Ontario Ministry of Health, Ontario, Canada
d University of Toronto Centre for Cardiovascular Research, Toronto, Canada
e Istituto "Mario Negri" Milano, Italy
f University of Washington School of Medicine and Public Health, Washington, DC, U.S.A.
g Montreal Heart Institute, Montreal, Canada
h University of Alberta, Edmonton, Canada
i Career Scientist of the Medical Research Council of Canada, Heart and Stroke Foundation of Ontario Endowed Research Chair
revised November 29, 1999; accepted December 1, 1999
Abstract
Aims In addition to diabetes mellitus, less severe abnormalities of glucose and insulin metabolism may be related to functional status in patients with heart failure. We examined the relationship of hyperglycaemia (
6·1mmol.l1) and hyperinsulinaemia (
11·2mU.l1) to functional status and cardiac function in patients with heart failure.
Methods and Results Fasting plasma glucose and insulin levels were obtained in 663 heart failure patients. The average left ventricular ejection fraction was 0·28±0·07, 63% were in New York Heart Association Functional Class (NYHA-FC) I/II and 37% were in NYHA-FC III/IV. Twenty seven percent had diabetes mellitus, but an additional 8% had undiagnosed diabetes mellitus (glucose
7mmol.l1) and 9% had glucose levels between 6·1 and 7mmol.l1, so that a total of 43% (287) of patients had elevated glucose levels (
6·1mmol.l1). In general, more diabetic patients had NYHA-FC III/IV symptoms, shorter 6min walk distances, but similar left ventricular ejection fractions compared to non-diabetic patients. The non-diabetic patients in NYHA-FC III/IV had higher glucose and insulin levels than patients in NYHA-FC I/II (6·3±0·2 vs 5·6±0·1mmol.l1,P <0·001 and 19·6±2·3 vs 10·2±0·6mU.l1, P<0·001). Non-diabetic patients with elevated glucose levels had shorter 6min walk distances compared to those with normal glucose levels (368·2±8m vs 389·±4m, P=0·02), however, left ventricular ejection fraction was similar.
Conclusion Glucose abnormalities are extremely common in heart failure patients (43% of patients). Diabetes mellitus and hyperglycaemia or hyperlinsulinaemia in non-diabetic patients were related to worse symptomatic status but not worsening left ventricular ejection fraction compared to patients with normal glucose and insulin levels.
Key Words: Glucose, insulin resistance, heart failure
f1 Correspondence: Dr R. S. McKelvie, Rm 341 McMaster Clinic, Hamilton Health Sciences CorporationGeneral Site, 237 Barton St East, Hamilton, ON, L8L 2X2, Canada.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
S. Sixt, S. Beer, M. Bluher, N. Korff, T. Peschel, M. Sonnabend, D. Teupser, J. Thiery, V. Adams, G. Schuler, et al. Long- but not short-term multifactorial intervention with focus on exercise training improves coronary endothelial dysfunction in diabetes mellitus type 2 and coronary artery disease Eur. Heart J., September 30, 2009; (2009) ehp398v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. W. Roberts, A. L. Clark, and K. K. Witte Review article: Left ventricular dysfunction and heart failure in metabolic syndrome and diabetes without overt coronary artery disease -- do we need to screen our patients? Diabetes and Vascular Disease Research, July 1, 2009; 6(3): 153 - 163. [Abstract] [PDF] |
||||
![]() |
M. A. ALZadjali, V. Godfrey, F. Khan, A. Choy, A. S. Doney, A. K. Wong, J. R. Petrie, A. D. Struthers, and C. C. Lang Insulin resistance is highly prevalent and is associated with reduced exercise tolerance in nondiabetic patients with heart failure. J. Am. Coll. Cardiol., March 3, 2009; 53(9): 747 - 753. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Sacca Heart Failure as a Multiple Hormonal Deficiency Syndrome Circ Heart Fail, March 1, 2009; 2(2): 151 - 156. [Full Text] [PDF] |
||||
![]() |
R. T. Zamanian, G. Hansmann, S. Snook, D. Lilienfeld, K. M. Rappaport, G. M. Reaven, M. Rabinovitch, and R. L. Doyle Insulin resistance in pulmonary arterial hypertension Eur. Respir. J., February 1, 2009; 33(2): 318 - 324. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. MacDonald, P. S. Jhund, M. C. Petrie, J. D. Lewsey, N. M. Hawkins, S. Bhagra, N. Munoz, F. Varyani, A. Redpath, J. Chalmers, et al. Discordant Short- and Long-Term Outcomes Associated With Diabetes in Patients With Heart Failure: Importance of Age and Sex: A Population Study of 5.1 Million People in Scotland Circ Heart Fail, November 1, 2008; 1(4): 234 - 241. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Aquilani, C. Opasich, A. Gualco, M. Verri, A. Testa, E. Pasini, S. Viglio, P. Iadarola, O. Pastoris, M. Dossena, et al. Adequate energy-protein intake is not enough to improve nutritional and metabolic status in muscle-depleted patients with chronic heart failure Eur J Heart Fail, November 1, 2008; 10(11): 1127 - 1135. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. MacDonald, M. C. Petrie, F. Varyani, J. Ostergren, E. L. Michelson, J. B. Young, S. D. Solomon, C. B. Granger, K. Swedberg, S. Yusuf, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme Eur. Heart J., June 1, 2008; 29(11): 1377 - 1385. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. MacDonald, M. C. Petrie, N. M. Hawkins, J. R. Petrie, M. Fisher, R. McKelvie, D. Aguilar, H. Krum, and J. J.V. McMurray Diabetes, left ventricular systolic dysfunction, and chronic heart failure Eur. Heart J., May 2, 2008; 29(10): 1224 - 1240. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Kistorp, A. Y. Chong, F. Gustafsson, S. Galatius, I. Raymond, J. Faber, G. Y.H. Lip, and P. Hildebrandt Biomarkers of endothelial dysfunction are elevated and related to prognosis in chronic heart failure patients with diabetes but not in those without diabetes Eur J Heart Fail, April 1, 2008; 10(4): 380 - 387. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Fantoni, F. Regoli, A. Ghanem, S. Raffa, C. Klersy, A. Sorgente, F. Faletra, M. Baravelli, L. Inglese, J. A. Salerno-Uriarte, et al. Long-term outcome in diabetic heart failure patients treated with cardiac resynchronization therapy Eur J Heart Fail, March 1, 2008; 10(3): 298 - 307. [Abstract] [Full Text] [PDF] |
||||
![]() |
C Berry, M Brett, K Stevenson, J J V McMurray, and J Norrie Nature and prognostic importance of abnormal glucose tolerance and diabetes in acute heart failure Heart, March 1, 2008; 94(3): 296 - 304. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Witteles and M. B. Fowler Insulin-Resistant Cardiomyopathy: Clinical Evidence, Mechanisms, and Treatment Options J. Am. Coll. Cardiol., January 15, 2008; 51(2): 93 - 102. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Torp-Pedersen, M. Metra, A. Charlesworth, P. Spark, M. A. Lukas, P. A Poole-Wilson, K. Swedberg, J. G F Cleland, A. Di Lenarda, W. J Remme, et al. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET) Heart, August 1, 2007; 93(8): 968 - 973. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ashrafian, M. P. Frenneaux, and L. H. Opie Metabolic Mechanisms in Heart Failure Circulation, July 24, 2007; 116(4): 434 - 448. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. V. Leier and G. J. Haas Diabetes and Heart Failure: The Role of Thiazolidinediones in Managing These Partners in Crime J. Am. Coll. Cardiol., July 3, 2007; 50(1): 37 - 39. [Full Text] [PDF] |
||||
![]() |
D. Aronson, H. Hammerman, M. R. Kapeliovich, A. Suleiman, Y. Agmon, R. Beyar, W. Markiewicz, and M. Suleiman Fasting Glucose in Acute Myocardial Infarction: Incremental value for long-term mortality and relationship with left ventricular systolic function Diabetes Care, April 1, 2007; 30(4): 960 - 966. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Petrie and J. J.V. McMurray Dysglycemia and Heart Failure Hospitalization: What Is the Link? Circulation, March 20, 2007; 115(11): 1334 - 1335. [Full Text] [PDF] |
||||
![]() |
S. von Haehling, W. Doehner, and S. D Anker Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure Cardiovasc Res, January 15, 2007; 73(2): 298 - 309. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Barsheshet, M. Garty, E. Grossman, A. Sandach, B. S. Lewis, S. Gottlieb, A. Shotan, S. Behar, A. Caspi, R. Schwartz, et al. Admission Blood Glucose Level and Mortality Among Hospitalized Nondiabetic Patients With Heart Failure. Arch Intern Med, August 14, 2006; 166(15): 1613 - 1619. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Liao, S. Takashima, H. Zhao, Y. Asano, Y. Shintani, T. Minamino, J. Kim, M. Fujita, M. Hori, and M. Kitakaze Control of plasma glucose with alpha-glucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice Cardiovasc Res, April 1, 2006; 70(1): 107 - 116. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ingelsson, J. Arnlov, J. Sundstrom, B. Zethelius, B. Vessby, and L. Lind Novel Metabolic Risk Factors for Heart Failure J. Am. Coll. Cardiol., December 6, 2005; 46(11): 2054 - 2060. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Doehner, M. Rauchhaus, P. Ponikowski, I. F. Godsland, S. von Haehling, D. O. Okonko, F. Leyva, A. J. Proudler, A. J.S. Coats, and S. D. Anker Impaired Insulin Sensitivity as an Independent Risk Factor for Mortality in Patients With Stable Chronic Heart Failure J. Am. Coll. Cardiol., September 20, 2005; 46(6): 1019 - 1026. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ingelsson, J. Sundstrom, J. Arnlov, B. Zethelius, and L. Lind Insulin Resistance and Risk of Congestive Heart Failure JAMA, July 20, 2005; 294(3): 334 - 341. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Dahlstrom Frequent non-cardiac comorbidities in patients with chronic heart failure Eur J Heart Fail, March 16, 2005; 7(3): 309 - 316. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Gustafsson, B. Brendorp, M. Seibaek, H. Burchardt, P. Hildebrandt, L. Kober, C. Torp-Pedersen, and DIAMOND Study Group Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure J. Am. Coll. Cardiol., March 3, 2004; 43(5): 771 - 777. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nodari, M. Metra, A. D. Cas, and L. D. Cas Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus Eur J Heart Fail, December 1, 2003; 5(6): 803 - 809. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kemppainen, H. Tsuchida, K. Stolen, H. Karlsson, M. Bjornholm, O. J Heinonen, P. Nuutila, A. Krook, J. Knuuti, and J. R Zierath Insulin signalling and resistance in patients with chronic heart failure J. Physiol., July 1, 2003; 550(1): 305 - 315. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A Lygate, K. Hulbert, M. Monfared, M. A Cole, K. Clarke, and S. Neubauer The PPAR{gamma}-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction Cardiovasc Res, June 1, 2003; 58(3): 632 - 637. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bartnik, K. Malmberg, and L. Ryden Diabetes and the heart: compromised myocardial function -- a common challenge Eur. Heart J. Suppl., January 1, 2003; 5(suppl_B): B33 - B41. [Abstract] [PDF] |
||||
![]() |
A. Norhammar and K. Malmberg Heart failure and glucose abnormalities: an increasing combination with poor functional capacity and outcome Eur. Heart J., August 2, 2000; 21(16): 1293 - 1294. [PDF] |
||||













